Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 3Lung Neoplasms 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Intraductal, Noninfiltrating 1Cachexia 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1

Interventions

Tamoxifen 10Specimen Handling 5Chemotherapy, Adjuvant 5Radiotherapy 3Mastectomy, Segmental 3Anastrozole 3Simvastatin 2telapristone acetate 1ruxolitinib 1exemestane 1abemaciclib 1Vinorelbine 1Trastuzumab 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Sugars 1Starch 1Soybean Proteins 1Radiation Dose Hypofractionation 1Radiation 1Protons 1Proton Therapy 1Probiotics 1Pharmacogenomic Testing 1Omacor 1Neoadjuvant Therapy 1Naltrexone 1Mastectomy, Subcutaneous 1Lovastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Carcinoma In Situ × Omacor × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡